Literature DB >> 12379823

Nitric oxide in heart failure: friend or foe.

Bodh I Jugdutt1.   

Abstract

Nitric oxide (NO) is a controversial molecule. It is either beneficial or deleterious. As with NO donors, one reason for this duality is related to the dose. Small doses are highly beneficial, maintaining blood flow in vessels and blood pressure, and protecting against foreign invaders. In high doses, it results in hypotension, forms peroxynitrite which is cytotoxic, and contributes to heart failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12379823     DOI: 10.1023/a:1020767731450

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.214


  31 in total

Review 1.  NO news is good news.

Authors:  E Culotta; D E Koshland
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

2.  Cardioprotection and attenuation of endothelial dysfunction by organic nitric oxide donors in myocardial ischemia-reperfusion.

Authors:  M R Siegfried; J Erhardt; T Rider; X L Ma; A M Lefer
Journal:  J Pharmacol Exp Ther       Date:  1992-02       Impact factor: 4.030

3.  Nitroglycerin: a homeopathic remedy.

Authors:  W B Fye
Journal:  Circulation       Date:  1986-01       Impact factor: 29.690

4.  The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Br J Pharmacol       Date:  1987-11       Impact factor: 8.739

Review 5.  Angiotensin II and nitric oxide interaction.

Authors:  Marc de Gasparo
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

Review 6.  Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis.

Authors:  Kai C Wollert; Helmut Drexler
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

7.  Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness.

Authors:  J M Hare; M M Givertz; M A Creager; W S Colucci
Journal:  Circulation       Date:  1998-01-20       Impact factor: 29.690

8.  Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes.

Authors:  M G Vila-Petroff; A Younes; J Egan; E G Lakatta; S J Sollott
Journal:  Circ Res       Date:  1999-05-14       Impact factor: 17.367

9.  Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location.

Authors:  B I Jugdutt; J W Warnica
Journal:  Circulation       Date:  1988-10       Impact factor: 29.690

10.  Myocardial salvage by intravenous nitroglycerin in conscious dogs: loss of beneficial effect with marked nitroglycerin-induced hypotension.

Authors:  B I Jugdutt
Journal:  Circulation       Date:  1983-09       Impact factor: 29.690

View more
  1 in total

1.  Crosstalk between AMPK activation and angiotensin II-induced hypertrophy in cardiomyocytes: the role of mitochondria.

Authors:  Jessica Soto Hernández; Giselle Barreto-Torres; Andrey V Kuznetsov; Zaza Khuchua; Sabzali Javadov
Journal:  J Cell Mol Med       Date:  2014-01-20       Impact factor: 5.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.